On 6 November 2006, orphan designation (EU/3/06/420) was granted by the European Commission to Wyeth Europa Limited, United Kingdom, for temsirolimus for the treatment of mantle cell lymphoma.
The sponsorship was transferred to Pfizer Limited, United Kingdom, in September 2011.
Temsirolimus in treatment of mantle cell lymphoma has been authorised in the EU as Torisel 21 August 2009.
The sponsorship was transferred to Pfizer Europe MA EEIG, Belgium, in July 2018.
Treatment of mantle cell lymphoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: